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Meeting ReportProblems and Solutions
for Circuits and Synapses
in Parkinson’s Disease
pharmacological substitution therapy provided by
L-dopa revolutionized the treatment of Parkinson’s dis-
ease (Tolosa et al., 1998). The alternative neurosurgical
treatment (pallidotomy) that was available prior to the
introduction of L-dopa in the 1950s was largely aban-
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McLean Hospital doned, since it was anticipated that L-dopa was a suffi-
cient treatment for Parkinson’s disease. Moreover, itBelmont, Massachusetts 02478
was hoped that this type of pharmacological substitu-
tion would be possible for many other neurodegenera-Introduction
The following is a synopsis of the discussions and con- tive diseases.
As it turned out, the situation wasn’t quite so simple.clusions from the meeting “Neuronal Degeneration and
Novel Therapeutic Approaches in Parkinson’s Disease” While L-dopa is a remarkably effective treatment, after
5 to 10 or 15 years of treatment, L-dopa becomes lessthat was convened at the Juan March Center for Interna-
tional Meetings on Biology Workshops in Madrid. The effective in a manner that is quite distinct from typical
drug-induced tolerance. For instance, patients experi-organizers were C.W. Olanow (Mt. Sinai Medical Center,
NY), Jose A. Obeso (University of Navarra, Pamplona), ence severe fluctuations in the drug effect. The so-called
“OFF” phenomenon describes the time when the drugand Rosario Moratalla (Instituto Cajal, Madrid). The or-
ganizers and the Instituto Juan March brought together somehow becomes ineffective for the patient. At such
times, the patient freezes up momentarily and losesa strong group of clinicians and basic scientists, and in
doing so, they hosted a scientifically as well as medically mobility. The “ON” times are when the drug works and
the patient gains mobility. However, both the ON andrelevant state-of-the-art workshop on brain systems
function and new therapeutic strategies that are relevant OFF times may be unfavorable. Symptoms can fluctuate
wildly with L-dopa treatment or analog drugs, in effectto Parkinson’s disease. In addition to providing a review
of some of the specific discussions and presentations resulting in problems during both the ON and OFF times.
During OFF times, freezing, rigidity, and an inability tofrom the meeting (due to space restrictions, it is not
possible to review all of the presentations), this report initiate movement is further compounded by side effects
during ON times, such as involuntary movements gener-is intended to serve the general reader with an overview
of this rapidly developing field. ated by the drug. These hyperactive movements and
dystonia (abnormal muscle tension and postures) areWithout pharmacological treatment, a typical person
afflicted with Parkinson’s disease displays a stiff posture very debilitating. Since the ON-OFF phenomena in Par-
kinson’s disease are so debilitating, some neurosur-and slightly unstable gait, with trembling hands and
arms, and moves laboriously with short steps. The lack geons and neurologists have returned to brain surgery
as a means to restrain these symptoms. Likewise, deep-of movement control, tremors, instability in their posture,
gait disturbance, masked face, muscle rigidity, vocal brain electrical stimulation (DBS) of the subthalamic nu-
cleus has also been shown to alleviate some of thediminution, or additional autonomic reactions are physi-
cally as well as emotionally incapacitating, and many movement disorders of Parkinson’s disease (Benabid,
2003; Lozano et al., 2002; Welter et al., 2004).patients with Parkinson’s disease experience emotional
difficulties in dealing with the disease, although their What accounts for the loss of the effectiveness of
L-dopa therapy and what are the neurobiological mech-cognitive functions are largely unaffected. This surpris-
ing range of symptoms is caused by the relatively selec- anisms that underlie the ON-OFF phenomena? It is rea-
sonable to assume that one of the reasons L-dopative loss of a small population of approximately 500,000
dopaminergic neurons in the brain. These cells are situ- becomes less effective is that it cannot be taken up by
the depleted number of surviving dopaminergic neu-ated deep in the midbrain in a region called the substan-
tia nigra (literally meaning “black substance”) whose rons. If indeed these side effects associated with pro-
longed L-dopa therapy reflect a loss of these dopamin-distinctive coloration is caused by melanin produced by
the neurons in this region. It is the case that in the aging ergic neurons and their connections and not just the
loss of dopamine, then the design of new therapeuticsbrain some of these dopaminergic neurons will stop
functioning properly over time; yet, the normally aging may need to deal with more than just the replacement
of a single substance, dopamine, and rather we arebrain somehow manages to compensate for the loss of
about 70%–80% of these cells or their synapses over left with the more complex issue of trying to recreate
synaptic networks and/or preserve them from degenera-time. It is only when a very small number of functional
dopaminergic synapses remain that the symptoms of tion (Isacson et al., 2003).
Parkinson’s disease appear.
The use of L-dopa as a therapy for the treatment of The Physiological State of Neuronal Circuitry
Parkinson’s disease has been hailed as one of the most that Contributes to the Signs
successful examples of drug therapies for the treatment and Symptoms of Parkinson’s Disease
of any neurological disease. When first introduced, the In order to understand the causes of Parkinson’s dis-
ease and develop effective alternative therapies for the
disease, it will ultimately be critical to understand the*Correspondence: isacson@hms.harvard.edu
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neural circuitry affected by the disease. The abnormal tions between the striatonigral and thalamocortical net-
works allow for feedforward and feedback transfer offunction of the neuronal connections that generates Par-
kinsonism is typically described as being centered information (Haber, 2003). When these circuits go
awry—with the loss of dopamine and synaptic controlwithin the basal ganglia regions of the brain. Loss of
dopaminergic neurons in the substantia nigra and ulti- in putamen in Parkinson’s disease, the increased firing
rate of the globus pallidus, and the similarly overactivemately a decline in dopamine levels result in abnormal
striatal neuronal physiology, which is followed by dys- subthalamic nucleus—surgical intervention can be an
effective treatment option (Welter et al., 2004). Indeed,function in the pallidal nuclei. Dr. Peter Strick (Depart-
ments of Neurobiology, Psychiatry, and Neurological such surgery prevents the dopamine loss-induced feed-
back inhibition of initiation of movement seen in Parkin-Surgery, University of Pittsburgh, PA) discussed which
cortical areas are the targets of these basal ganglia son’s disease. However, some dopamine function is still
required for such surgical interventions to be effective,outputs and showed that the functionally segregated
circuits that arise from the basal ganglia also have a and the primary desired effect in patients is to remove
their drug-induced side effect through the basal gan-surprising degree of topographic organization in the ce-
rebral cortex (Middleton and Strick, 2002). These experi- glia loops.
ments indicate that there may be a widespread effect
of basal ganglia in the processes that would underlie Synaptic Interactions and the Role of Dopamine
some of the pre- or nonmotor effects that are seen in Receptors in the Function and Dysfunction
Parkinson’s disease as well as Huntington’s disease. of the Dopamine System
In keeping with this theme of complexity and wide Dr. Rosario Moratalla described the roles of dopamine
reach of the basal ganglia system, there is also evidence D1 and D2 receptor subtypes in L-dopa-induced dyski-
that ventral putamen may also participate in a circuit that nesia models of Parkinson’s disease. D1 receptor knock-
receives input from the amygdala and that this pathway out mice have reduced dyskinesia. This contrasts with
would then provide the limbic system with access to knockout mice lacking D2 receptors, which show an ele-
the motor cortex. This slightly broader view of basal vation of some dyskinesias after L-dopa inducement
ganglia function was also the message put forward by (Centonze et al., 2003a, 2003b; Xu et al., 1994). The
Dr. Yves Agid (Hopital de la Salpetriere, INSERM U289, implication of these studies is that a functional balance
Paris, France), who presented evidence suggesting a of dopamine D1/D2 receptors is required for the normal
role for basal ganglia in obsessive-compulsive disorders maintenance and function of the basal ganglia circuitry
(Houeto et al., 2002). The implication of these studies involved in the control of movements. Dr. Paolo Cala-
is that, in various contexts, the classic limbic circuits bresi (Department of Neuroscience, University of Rome,
also have access to pallidum, the subthalamic nucleus, Rome, Italy) presented data to suggest a role for striatal
substantia nigra, and thalamus. Dr. Ann M. Graybiel synaptic plasticity in L-dopa-induced dyskinesias. High-
(Massachusetts Institute of Technology, Cambridge, frequency stimulation of cortical afferents will induce
LTP, and in both control rats and L-dopa-treated Parkin-MA) presented work examining the hypothesis that the
sonian rats that did not display dyskinesias, subsequentbrain systems that include striatum are involved in adap-
low-frequency stimulation of these synapses results intive mechanisms used to adjust cerebral cortical activity
depotentiation of the response. This effect is dependentto various behaviors, including motor and action plans.
on the D1 class of dopamine receptor. However, in dys-Using multiple electrode recordings, Graybiel and col-
kinetic rats, such low-frequency stimulation does notleagues demonstrated that the normal function of the
lead to a depotentiation or reversal of the LTP effect.cortical striatal and associated thalamocortical systems
This work suggests that the abnormal synaptic plasticityas well as other corticofugal systems can be finely tuned
and the loss of homeostatic control of this circuit maybased on prior actions and movements executed
be linked with the development of L-dopa-induced dys-through this circuitry (Courtemanche et al., 2003). While
kinesias (Picconi et al., 2003). Dr. Christian Gross pro-none of these speakers addressed the particular dopa-
vided additional insight into how the abnormal circuitryminergic abnormalities seen in Parkinson’s disease, the
associated with Parkinson’s disease affects output (Uni-themes that they highlighted concerning the role of basal
versity of Bordeaux, Bordeaux, France). Using the MPTPganglia in premotor and motor control are very likely to
model of Parkinson’s disease, Dr. Gross described pre-be important for understanding the mechanisms under-
symptomatic and symptomatic shifts in DA function thatlying the motor control symptoms seen in Parkinson’s
are similar to those seen in Parkinson’s patients. Keypatients, as abnormalities of these basal ganglia circuits
components of this shift were increases in dopamineare thought to underlie both the motor control deficits
metabolism (as described previously) as well as anin patients with the disease and the drug-induced side
upregulation of the dopamine D2 receptor. It was alsoeffects. The various hypotheses for how abnormal acti-
proposed that the subthalamic nucleus and globus pal-vation of the basal ganglia leads to tremor and rigidity
lidus would also increase their firing rates as a form ofare perhaps best explained by the work of Alexander et
compensation for the initial loss of dopamine (Meissneral. (1990), who demonstrated an abnormal synchroniza-
et al., 2003).tion of pallidal neuronal discharge due to the loss of
dopamine in the system. Finally, to account for the role
of the basal ganglia in both motor execution and motor What Are the Genetic and Environmental
Contributions to Parkinson’s Disease and Howlearning, Susan Haber has suggested a model involving
an integrated network of connections betwen the basal Can This Pathophysiology Be Corrected?
In recent years, it has become clear that both intrinsic/ganglia and frontal cortex that controls goal-directed
motor behavior. Reciprocal and nonreciprocal connec- genetic and extrinsic/environmental factors contribute
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to Parkinson’s disease. Dr. William Langston (Parkin- understanding of this system will lead to solutions to
these problems. For instance, there is much evidenceson’s Institute, Sunnyvale, CA) presented data to sug-
of inherent brain plasticity, suggesting that it may begest that environmental factors may affect the symp-
possible to design therapies that take advantage of thistoms associated with late-onset Parkinson’s disease
intrinsic plasticity and may therefore be more effective in(Tanner et al., 1999). On the other hand, in recent years
the overall treatment of the disease than current drugs.a number of susceptibility genes and genes related to
Finally, several speakers also discussed alternative synuclein and parkin have been implicated in the
transplantation approaches, for instance, the trans-pathophysiology of both idiopathic and genetic disease
plantation of neural stem cells or embryonic stem cells.(Farrer et al., 2001, 2004; Tan et al., 2003). Whatever the
Dr. Ole Isacson (Harvard Medical School, Boston, MA)root, the obvious question that arises is how to halt the
and Dr. Ernest Arenas (Karolinska Institute, Stockholm,pathological progression of the disease. Dr. C. Warren
Sweden) made the case for stem cell-based cell replace-Olanow discussed the role of the ubiquitin proteasome
ment and neuroprotection strategies as alternatives tosystem in the disease. Dr. Olanow presented evidence
fetal dopamine cell transplantation. First, Dr. Arenas de-to show that it is possible to experimentally induce major
scribed the molecules and pathways that are involveddegeneration in the dopaminergic system by means of
in normal neurogenesis and proliferation of midbrainprotein misfolding. This idea was further elaborated by
dopaminergic neurons (Castelo-Branco et al., 2003) andDr. Mark Cookson (National Institutes of Health,
focused specifically on the role of the Wnt family in theBethesda, MD), who showed that overexpression of mu-
regulation of the proliferation of Nurr-1-positive precur-tant or normal  synuclein or exposure to proteosome
sors. Insights that come with the understanding of theinhibitor can result in selective toxicity of midbrain dopa-
normal pathways that control dopaminergic develop-mine neurons (Singleton et al., 2003; Cookson, 2003a,
ment may be useful for designing strategies to generate2003b). Proteosomal dysfunction may in fact be a com-
dopaminergic neurons from other sources, such as ESmon component of many neurodegenerative diseases.
cells or neuronal stem cell populations. Patrik Brundin
(Lund University, Lund, Sweden) reviewed recent evi-
Neural Connectivity and Synapse Repair dence in the field suggesting that ES cells may be a
The final part of the meeting revolved around potential reasonable starting point and cell source for generating
therapies. Andreas Lozano (University of Toronto, To- the midbrain dopamine neurons for future transplanta-
ronto, Canada) presented examples of surgical thera- tion and could overcome some of the technical and
pies that have been shown to be effective in treating political problems associated with using a mixture of
aspects of the disease (Lozano et al., 2002). Dr. Lozano fetal primary neurons. Previous work has shown that
also presented a review of gene therapy approaches mouse dopaminergic neurons can be expanded in a cell
and potential cell transplantation therapeutics that are culture dish from growth factor expanded E12 ventral
currently under investigation. The use of fetal mesence- mesencephalic precursor cells, as well as from trans-
phalic dopamine cell transplants has been the focus of fected ES and progenitor cell cultures (for examples,
much interest and investigation in the field. Functional see Wagner et al., 1999; Kawasaki et al., 2000; Lee et
motor deficits associated with Parkinson’s disease can al., 2000; Chung et al., 2002; Kim et al., 2002; Castelo-
be reduced after fetal dopaminergic cell transfer to the Branco et al., 2003). More importantly, undifferentiated
human caudate-putamen. Interestingly, these fetal do- ES cells or embryoid bodies can be injected into the
paminergic cells appear to be resistant to the underlying brain and can there spontaneously differentiate into
disease process that continues to destroy the patient’s neurons (Deacon et al., 1998). Further, naive or prediffer-
own dopaminergic system, even after transplantation entiated ES cells implanted into a dopamine-depleted
(Piccini et al., 1999, 2000). That said, the approach is striatum can develop and function as replicas of the
not without problems and side effects. For instance, a dopaminergic neurons that are lost in Parkinson’s dis-
subset of transplanted patients develop dyskinesias ease and can restore amphetamine-induced motor sym-
after transplantation. It has been proposed that the un- metry and cortical activation (Bjorklund et al., 2002;
regulated release of dopamine from fetal neurons is the Kim et al., 2002) that are lost in Parkinson’s disease.
cause of unwanted dyskinesias seen in these patients In conclusion, this meeting highlighted the tremen-
dous progress that has been made in recent years in(Freed et al., 2001; Olanow et al., 2003). In addition,
both our understanding of the pathogenesis of Parkin-despite the apparent successes of the fetal cell trans-
son’s disease and in the development of therapeuticsplantation approach, clinical trials aimed at assessing
to treat the disease. If there is one theme to be takenmore systematically the therapeutic value of this ap-
away from this meeting, it is that Parkinson’s disease isproach have met with mixed results. Dr. Stanley Fahn
a multisystems disease, affecting a widespread circuitry(Columbia University, NY), presented a review of the
beyond just the substantia nigra, and efforts aimed atrecent double-blind clinical trials using mesencephalic
developing novel therapeutic treatments will certainlyderived cell transplants as a Parkinson’s disease ther-
need to grapple with this complexity. While there areapy (Freed et al., 2001). Dr. Fahn outlined the lessons
many reasons to be optimistic that better treatmentslearned and made recommendations for the design and
for Parkinson’s disease are within sight, it is also clearapproach of future studies (Freed et al., 2001; Olanow
that many challenges still remain.et al., 2003). Several speakers also argued that, in evalu-
ating the potential of various therapeutic approaches,
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